CN103492416A - 用于癌症中使用的抗il-1r1抑制剂 - Google Patents

用于癌症中使用的抗il-1r1抑制剂 Download PDF

Info

Publication number
CN103492416A
CN103492416A CN201280018582.5A CN201280018582A CN103492416A CN 103492416 A CN103492416 A CN 103492416A CN 201280018582 A CN201280018582 A CN 201280018582A CN 103492416 A CN103492416 A CN 103492416A
Authority
CN
China
Prior art keywords
csc
polypeptide
cells
cancer
il1r1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280018582.5A
Other languages
English (en)
Chinese (zh)
Inventor
A.泽希雷
M.沃尔夫
R.蒂格
H.萨布泽瓦里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN103492416A publication Critical patent/CN103492416A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280018582.5A 2011-04-15 2012-04-13 用于癌症中使用的抗il-1r1抑制剂 Pending CN103492416A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11003183.8 2011-04-15
EP11003183 2011-04-15
PCT/US2012/033490 WO2012142391A1 (en) 2011-04-15 2012-04-13 Anti- il-1r1 inhibitors for use in cancer

Publications (1)

Publication Number Publication Date
CN103492416A true CN103492416A (zh) 2014-01-01

Family

ID=46018101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280018582.5A Pending CN103492416A (zh) 2011-04-15 2012-04-13 用于癌症中使用的抗il-1r1抑制剂

Country Status (8)

Country Link
US (1) US20140308294A1 (https=)
EP (1) EP2697260A1 (https=)
JP (1) JP2014519480A (https=)
CN (1) CN103492416A (https=)
AU (1) AU2012242666A1 (https=)
CA (1) CA2833147A1 (https=)
IL (1) IL228847A0 (https=)
WO (1) WO2012142391A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033216A (zh) * 2015-12-08 2017-08-11 财团法人农业科技研究院 靶向癌干细胞的胜肽和其应用
CN109415442A (zh) * 2016-05-06 2019-03-01 Mab发现股份有限公司 人源化抗il-1r3抗体
CN109468380A (zh) * 2018-10-31 2019-03-15 复旦大学附属肿瘤医院 Il1r2在乳腺癌预后评估与靶向治疗中的应用
CN110431225A (zh) * 2017-03-10 2019-11-08 默克专利股份公司 受感染的细胞培养物
CN112512637A (zh) * 2018-05-29 2021-03-16 昂科霍斯特公司 通过阻断宿主诱导的il-1与放射疗法组合治疗癌症

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
CN113316587B (zh) * 2019-05-20 2024-03-26 南通壹宸生物医药科技有限公司 一种双特异性分子及其制备与用途
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
CN1742021A (zh) * 2002-09-06 2006-03-01 安姆根有限公司 治疗性人抗－il－1r1 单克隆抗体
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2011021014A2 (en) * 2009-08-21 2011-02-24 Cantargia Ab Novel agents and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215434B (hu) 1988-05-27 1999-04-28 Synergen Inc. Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
IL150103A0 (en) 1999-12-10 2002-12-01 Amgen Inc Interleukin-1 receptor antagonist-like molecules and uses thereof
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
HUE029021T2 (en) 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
CN1742021A (zh) * 2002-09-06 2006-03-01 安姆根有限公司 治疗性人抗－il－1r1 单克隆抗体
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2011021014A2 (en) * 2009-08-21 2011-02-24 Cantargia Ab Novel agents and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEIJI YANO等: "Multifunctional interleukin-1β promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules", 《CANCER SCI》, vol. 94, no. 3, 28 February 2003 (2003-02-28), pages 244 - 252 *
ULF HARNACK等: "IL-1 Receptor Antagonist Anakinra Enhances Tumour Growth Inhibition in Mice Receiving Peptide Vaccination and β-(1-3),(1-6)-D-Glucan", 《ANTICANCER RESEARCH》, vol. 30, no. 10, 31 October 2010 (2010-10-31), pages 3959 - 3966 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033216A (zh) * 2015-12-08 2017-08-11 财团法人农业科技研究院 靶向癌干细胞的胜肽和其应用
CN107033216B (zh) * 2015-12-08 2021-08-03 财团法人农业科技研究院 靶向癌干细胞的胜肽和其应用
CN109415442A (zh) * 2016-05-06 2019-03-01 Mab发现股份有限公司 人源化抗il-1r3抗体
CN109415442B (zh) * 2016-05-06 2022-12-23 赛诺菲生物技术公司 人源化抗il-1r3抗体
CN110431225A (zh) * 2017-03-10 2019-11-08 默克专利股份公司 受感染的细胞培养物
CN110431225B (zh) * 2017-03-10 2024-04-12 默克专利股份公司 受感染的细胞培养物
CN112512637A (zh) * 2018-05-29 2021-03-16 昂科霍斯特公司 通过阻断宿主诱导的il-1与放射疗法组合治疗癌症
CN109468380A (zh) * 2018-10-31 2019-03-15 复旦大学附属肿瘤医院 Il1r2在乳腺癌预后评估与靶向治疗中的应用
CN109468380B (zh) * 2018-10-31 2022-05-17 复旦大学附属肿瘤医院 Il1r2在乳腺癌预后评估与靶向治疗中的应用

Also Published As

Publication number Publication date
JP2014519480A (ja) 2014-08-14
CA2833147A1 (en) 2012-10-18
US20140308294A1 (en) 2014-10-16
IL228847A0 (en) 2013-12-31
EP2697260A1 (en) 2014-02-19
AU2012242666A1 (en) 2013-11-28
WO2012142391A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
CN103492416A (zh) 用于癌症中使用的抗il-1r1抑制剂
Argyle et al. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors
Phillips et al. The stromal derived factor–1/CXCL12–CXC chemokine receptor 4 biological axis in non–small cell lung cancer metastases
Li et al. Low levels of tumor necrosis factor α increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site
Kryczek et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers
UA128387C2 (uk) Антитіло до lag3
Jin et al. Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6
CN113677706B (zh) 肝毒性的治疗
Gao et al. Chemokine CCL15 mediates migration of human bone marrow-derived mesenchymal stem cells toward hepatocellular carcinoma
Vela et al. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for sarcoma immunotherapy
US20230019381A1 (en) Nk cell-based therapy
Zhang et al. Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
KR20250052412A (ko) 항-인간 표피성장인자 수용체 2(her2) 키메라 항원 수용체(car)를 포함하는 자연살해세포를 투여하는 방법
CN118290584A (zh) 一种包括nk细胞的药物组合物及其在制备治疗肿瘤药物中的应用
US12202904B2 (en) IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
CN119562815A (zh) Gpcr抑制剂及其用途
Davies et al. Novel therapeutic targets in multiple myeloma
Lee et al. Stimulation of the molecule 4-1BB enhances host defense against Listeria monocytogenes infection in mice by inducing rapid infiltration and activation of neutrophils and monocytes
CN121443626A (zh) 修饰的 γδ T细胞
JP4950885B2 (ja) 白血病における酵素阻害剤
US20230321105A1 (en) Cell signal detection and modulation in disease
US20250197513A1 (en) Osmr-specific monoclonal antibodies and methods of their use
US20250313648A1 (en) Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
US12427183B2 (en) Methods of treating cancer, infectious disease, and autoimmune disease using chemokines
US20250092126A1 (en) Treatment and prevention of alcoholic liver disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140101